CLEC9a Antibody (14N8D7) - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-27087

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human, Primate, Rhesus Macaque

Applications

Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 kappa Clone # 14N8D7

Format

BSA Free

Concentration

1.0 mg/ml

View all CLEC9a Antibodies »

Product Summary for CLEC9a Antibody (14N8D7) - BSA Free

Immunogen

A portion of amino acids 50-130 of human CLEC9A was used as the immunogen for the antibody.

Reactivity Notes

Orangutan, Chimp (100%), Canine, Panda, Equine (73%), Bovine (73%), Mouse (60%).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1 kappa

Scientific Data Images for CLEC9a Antibody (14N8D7) - BSA Free

Western Blot: CLEC9a Antibody (14N8D7)BSA Free [NBP2-27087]

Western Blot: CLEC9a Antibody (14N8D7)BSA Free [NBP2-27087]

Western Blot: CLEC9a Antibody (14N8D7) [NBP2-27087] - Analysis of A) HCT-116 and B) MCF-7 lysate using this antibody at 1 ug/ml.

Applications for CLEC9a Antibody (14N8D7) - BSA Free

Application
Recommended Usage

Western Blot

1-3ug/ml
Application Notes
CLEC9A is a glycoprotein visualized by western blot between ~25-45 kD.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Format

BSA Free

Preservative

0.05% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: CLEC9a

CLEC9A is a group V CTLR (C-type lectin-like receptor) that functions as an activation receptor and is expressed on myeloid lineage cellsThis protein is also expressed at the cell surface and acts as glycosylated dimers which mediate endocytosis, but not phagocytosis (Poulin LF et al, 2010). It facilitates antigen uptake and presentation, and may provide a suitable target for antibody-mediated antigen delivery. CLEC9A is important for conveying information from necrotic cells to T-cells and defines a pathway by which adaptive immune responses can be initiated in the absence of infection (Huysamen C et al, 2008). It recruits Syk to mediate sensing of necrosis by the principal DC subset involved in regulating cross priming to cell-associated antigens (Sancho D et al, 2009). Signaling via this kinase occurs through a novel pathway involving CARD9 which induce a variety of cellular responses including the induction of cytokines (such as TNF, IL-6, IL-10, IL-23, and IL-2), the respiratory burst, and the production of Arachidonic acid (Caminschi I et al, 2008). In addition, it also induces TH17 (T-helper type 17) adaptive responses in vivo. Expression of CLEC9A is highly restricted in peripheral blood, being detected only on BDCA3+ DCs and on a small subset of CD14+ CD16- monocytes. CLEC9A serves as a new marker to distinguish subtypes of DCs. Targeting antigens to DCs with antibodies to CLEC9A is a promising strategy to enhance the efficiency of vaccines, even in the absence of adjuvants (Sancho D et al, 2008).

Long Name

C-type Lectin-like Receptor 9

Alternate Names

CD370, DNGR1

Gene Symbol

CLEC9A

UniProt

Q6UXN8

Additional CLEC9a Products

Product Documents for CLEC9a Antibody (14N8D7) - BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CLEC9a Antibody (14N8D7) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.